Testing a cell therapy called MT027 in glioblastoma that has come back
Official title: The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests a cell therapy for people whose glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary has come back.
Read our full plain-language summary
What the trial team says
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy. Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10\^7 cells), safety follow-up, and long-term follow-up periods. MT027 will be given via ICV injection on Day 1 \& Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and disease progress in the first cycle, additional treatment may be continued bi-weekly in a 28-day cycle (Days 1 \& Day 15 of the 28-day cycle) until intolerable toxicity, disease progression, withdrawal from the study, or death, whichever comes first. After the last dose, there will be a safety follow-up period lasting for 1 year and then a long-term follow-up up to 15 years.
Key facts
- Registry number
- NCT07386002
- Stage of testing
- Phase 2
- Conditions studied
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Where it is running
This trial lists 4 sites.
-
Maryland
- The Johns Hopkins Sidney Kimmel Cancer Center (Baltimore)
-
Taiwan
- Hualien Tzu Chi Hospital (Hualien City)
- Chang Gung Memorial Hospital, Kaohsiung (Kaohsiung City)
- Chang Gung Memorial Hospital, Linkou (Taoyuan)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.